JP2021518397A5 - - Google Patents
Info
- Publication number
- JP2021518397A5 JP2021518397A5 JP2020550674A JP2020550674A JP2021518397A5 JP 2021518397 A5 JP2021518397 A5 JP 2021518397A5 JP 2020550674 A JP2020550674 A JP 2020550674A JP 2020550674 A JP2020550674 A JP 2020550674A JP 2021518397 A5 JP2021518397 A5 JP 2021518397A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- pharmaceutical composition
- composition according
- recurrent
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024052953A JP2024075771A (ja) | 2018-03-23 | 2024-03-28 | 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862647346P | 2018-03-23 | 2018-03-23 | |
| US62/647,346 | 2018-03-23 | ||
| US201862658276P | 2018-04-16 | 2018-04-16 | |
| US62/658,276 | 2018-04-16 | ||
| PCT/US2019/023516 WO2019183438A1 (en) | 2018-03-23 | 2019-03-22 | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024052953A Division JP2024075771A (ja) | 2018-03-23 | 2024-03-28 | 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518397A JP2021518397A (ja) | 2021-08-02 |
| JP2021518397A5 true JP2021518397A5 (https=) | 2022-03-30 |
| JPWO2019183438A5 JPWO2019183438A5 (https=) | 2022-03-30 |
Family
ID=66041744
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550674A Pending JP2021518397A (ja) | 2018-03-23 | 2019-03-22 | 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用 |
| JP2024052953A Pending JP2024075771A (ja) | 2018-03-23 | 2024-03-28 | 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024052953A Pending JP2024075771A (ja) | 2018-03-23 | 2024-03-28 | 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190290775A1 (https=) |
| EP (1) | EP3768714A1 (https=) |
| JP (2) | JP2021518397A (https=) |
| KR (1) | KR20200135841A (https=) |
| CN (1) | CN112189020A (https=) |
| AU (1) | AU2019240403A1 (https=) |
| BR (1) | BR112020018948A2 (https=) |
| CA (1) | CA3093731A1 (https=) |
| IL (1) | IL277338A (https=) |
| MA (1) | MA52135A (https=) |
| MX (1) | MX2020009842A (https=) |
| SG (1) | SG11202009264WA (https=) |
| TW (1) | TW202003047A (https=) |
| WO (1) | WO2019183438A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL283522B2 (en) | 2018-12-03 | 2025-03-01 | Agensys Inc | Pharmaceutical compositions containing anti-191P4D12 antibody drug conjugates and methods of using them |
| CN121422247A (zh) * | 2020-05-03 | 2026-01-30 | 乐普生物科技股份有限公司 | 抗体药物偶联物及其制剂 |
| PH12022553333A1 (en) * | 2020-06-19 | 2023-10-16 | Agensys Inc | Markers for use in methods for treating cancers with antibody drug conjugates (adc) |
| MX2023003404A (es) * | 2020-09-28 | 2023-03-31 | Seagen Inc | Anticuerpos anti-l1vi humanizados para el tratamiento del cancer. |
| AU2022238571A1 (en) | 2021-03-18 | 2023-09-14 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| IL312110A (en) | 2021-10-29 | 2024-06-01 | Seagen Inc | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate |
| EP4674436A1 (en) * | 2023-02-27 | 2026-01-07 | CSPC Megalith Biopharmaceutical Co., Ltd. | Pharmaceutical composition of recombinant humanized anti-nectin-4 monoclonal antibody-mmae conjugate drug |
| JP2026508672A (ja) * | 2023-03-17 | 2026-03-11 | ザイダス・ライフサイエンシーズ・リミテッド | ダラツムマブ薬物コンジュゲートおよびその調製 |
| EP4727971A1 (en) | 2023-06-13 | 2026-04-22 | Adcentrx Therapeutics Inc. | Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins |
| WO2025185617A1 (en) * | 2024-03-05 | 2025-09-12 | Hutchmed Limited | Linker, antibody-drug conjugate and use thereof |
| WO2025264533A1 (en) | 2024-06-17 | 2025-12-26 | Adcentrx Therapeutics Inc. | Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins |
| CN120713867A (zh) * | 2025-08-20 | 2025-09-30 | 中国人民解放军西部战区总医院 | 一种微管蛋白破坏剂二聚体与铜死亡药物联用的纳米颗粒、其制备方法及用途 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| AU667460B2 (en) | 1990-10-05 | 1996-03-28 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
| EP0557300B1 (en) | 1990-10-29 | 1997-11-19 | Chiron Corporation | Bispecific antibodies, method of production, and uses thereof |
| IE921342A1 (en) | 1991-04-26 | 1992-11-04 | Surface Active Ltd | Novel antibodies, and methods for their use |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| EP1306095A3 (en) | 1992-03-05 | 2003-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| ATE234635T1 (de) | 1995-12-22 | 2003-04-15 | Bristol Myers Squibb Co | Verzweigte hydrazongruppen enthaltende kuppler |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| AU2004213053C1 (en) | 2003-02-20 | 2009-07-16 | Seagen Inc. | Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| AU2005218642B2 (en) | 2004-03-02 | 2011-04-28 | Seagen Inc. | Partially loaded antibodies and methods of their conjugation |
| EP1817341A2 (en) * | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| NZ565075A (en) * | 2005-06-20 | 2011-05-27 | Psma Dev Company Llc | PSMA antibody-drug conjugates |
| RU2476441C2 (ru) | 2007-10-19 | 2013-02-27 | Сиэтл Дженетикс, Инк. | Cd19-связывающие средства и их применение |
| EP2265283B1 (en) | 2008-03-18 | 2014-09-03 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
| CA3159253A1 (en) | 2009-01-09 | 2010-07-15 | Seagen Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
| EP3409287B9 (en) | 2010-09-29 | 2021-07-21 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to 191p4d12 proteins |
| AU2011316917B2 (en) * | 2010-10-22 | 2016-02-25 | Seagen Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway |
| KR102023496B1 (ko) | 2011-04-21 | 2019-09-20 | 시애틀 지네틱스, 인크. | 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도 |
| AR090549A1 (es) * | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| ES2826398T3 (es) | 2013-10-15 | 2021-05-18 | Seagen Inc | Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco |
| ES2895623T3 (es) * | 2014-05-22 | 2022-02-22 | Byondis Bv | Conjugación de sitio específico de fármacos enlazadores con anticuerpos y ADC resultantes |
| SI3900742T1 (sl) | 2014-09-11 | 2024-10-30 | Seagen Inc. | Ciljana dostava zdravilnih snovi, ki vsebujejo terciarne amine |
| BR112017023862A2 (pt) * | 2015-05-04 | 2018-07-17 | Cytomx Therapeutics Inc | anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes |
| CN108367043A (zh) | 2015-12-04 | 2018-08-03 | 西雅图基因公司 | 季铵化的微管溶素化合物的缀合物 |
| CN109562172B (zh) * | 2016-08-11 | 2022-08-16 | 免疫医疗公司 | 抗HLA-DR抗体药物缀合物IMMU-140(hL243-CL2A-SN-38)在HLA-DR阳性癌症中的功效 |
-
2019
- 2019-03-22 CA CA3093731A patent/CA3093731A1/en active Pending
- 2019-03-22 TW TW108109929A patent/TW202003047A/zh unknown
- 2019-03-22 JP JP2020550674A patent/JP2021518397A/ja active Pending
- 2019-03-22 MX MX2020009842A patent/MX2020009842A/es unknown
- 2019-03-22 AU AU2019240403A patent/AU2019240403A1/en not_active Abandoned
- 2019-03-22 KR KR1020207030320A patent/KR20200135841A/ko not_active Ceased
- 2019-03-22 EP EP19715720.9A patent/EP3768714A1/en active Pending
- 2019-03-22 WO PCT/US2019/023516 patent/WO2019183438A1/en not_active Ceased
- 2019-03-22 SG SG11202009264WA patent/SG11202009264WA/en unknown
- 2019-03-22 CN CN201980033040.7A patent/CN112189020A/zh active Pending
- 2019-03-22 US US16/362,125 patent/US20190290775A1/en not_active Abandoned
- 2019-03-22 BR BR112020018948-0A patent/BR112020018948A2/pt not_active Application Discontinuation
- 2019-03-22 MA MA052135A patent/MA52135A/fr unknown
-
2020
- 2020-09-14 IL IL277338A patent/IL277338A/en unknown
-
2022
- 2022-07-21 US US17/870,749 patent/US20230110128A1/en not_active Abandoned
-
2024
- 2024-03-28 JP JP2024052953A patent/JP2024075771A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518397A5 (https=) | ||
| Cheng et al. | MORAb-202, an antibody–drug conjugate utilizing humanized anti-human FRα farletuzumab and the microtubule-targeting agent eribulin, has potent antitumor activity | |
| Ab et al. | IMGN853, a folate receptor-α (FRα)–targeting antibody–drug conjugate, exhibits potent targeted antitumor activity against FRα-expressing tumors | |
| AU2019320336B2 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| JP7386208B2 (ja) | 抗ｆｏｌｒ１免疫抱合体投薬レジメン | |
| Matsuzaki et al. | Anti‐glypican‐1 antibody‐drug conjugate exhibits potent preclinical antitumor activity against glypican‐1 positive uterine cervical cancer | |
| JP2019532056A5 (https=) | ||
| JP2024075771A (ja) | 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用 | |
| JP2017510559A5 (https=) | ||
| CN108348608B (zh) | 抗5t4抗体和抗体-药物缀合物 | |
| JP7547205B2 (ja) | 抗ｈｅｒ２バイパラトピック抗体－薬物コンジュゲート及び使用方法 | |
| JP2019536740A5 (https=) | ||
| JP2018520091A5 (https=) | ||
| Hicks et al. | The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models | |
| FI3930847T3 (fi) | Korkea-affiinisia anti-MERTK-vasta-aineita ja niiden käyttöjä | |
| HRP20170743T1 (hr) | Anti-ceacam5 protutijela i njihova uporaba | |
| JP2018502902A (ja) | ピロロベンゾジアゼピン−抗体コンジュゲート | |
| KR20180088445A (ko) | 신규한 항-클라우딘 항체 및 사용 방법 | |
| Crépin et al. | Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas | |
| JPWO2019183438A5 (https=) | ||
| Hartimath et al. | Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft | |
| Shinmi et al. | Novel anticarcinoembryonic antigen antibody–drug conjugate has antitumor activity in the existence of soluble antigen | |
| Krug et al. | Targeting Lewis Y (LeY) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels | |
| MX2025006057A (es) | Conjugados anticuerpo-farmaco anti-cea y metodos de uso | |
| Glatt et al. | Synthesis and Characterization of Cetuximab–Docetaxel and Panitumumab–Docetaxel Antibody–Drug Conjugates for EGFR-Overexpressing Cancer Therapy |